Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report-Reference-Cited by-同舟云学术

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report

Published:2023-02 Issue:2 Volume:4 Page:100456
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Enrico Diego^ORCID,Tsou Florencia,Catani Greta,Pupareli Carmen,Girotti María Romina,Ulloa Alvarez David Esteban,Waisberg Federico,Rodríguez Andrés,Reyes Roxana,Chacón Matías,Reguart Noemí,Martín Claudio

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Osimertinib in EGFR-mutated lung cancer: a review of the existing and emerging clinical data;Lee;Onco Targets Ther,2021

2. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer;Leonetti;Br J Cancer,2019

3. EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors;Ercan;Clin Cancer Res,2015

4. Acquired EGFR L718V mutation and loss of T790M-mediated resistance to osimertinib in a patient with NSCLC who responded to afatinib;Fang;J Thorac Oncol,2019

5. Resolving resistance to osimertinib therapy with afatinib in an NSCLC patient with EGFR L718Q mutation;Yang;Clin Lung Cancer,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC);Bioorganic & Medicinal Chemistry;2024-07

2. Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell Lung Cancer Cell Line H1975;Anticancer Research;2023-11-29

3. Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer;Current Topics in Medicinal Chemistry;2023-08